Staging efficacy of breast cancer with sentinel lymphadenectomy

Breast Cancer Research and Treatment

Volumn 57, Issue 2, 1999, Pages 221-229

  Noguchi, Masakuni ^a   Bando, Etsuro ^a   Tsugawa, Koichiro ^a   Miwa, Koichi ^a   Yokoyama, Kunihiko ^a   Nakajima, Ken ichi ^a   Michigishi, Takatoshi ^a   Tonami, Norihisa ^a   Minato, Hiroshi ^a   Nonomura, Akitaka ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Axillary dissection; Breast cancer; Prognosis; Sentinel node dissection

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELIABILITY;

EID: 0032737973     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006268426526     Document Type: Article

References (53)

1. Fisher B, Redmond C, Fisher ER, et al.: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312: 674-681, 1985
2. Lythgoe JP, Palmer MK: Manchester regional breast study - 5 and 10 years results. Br J Surg 69: 693-696, 1982
3. Cancer Research Campaign Work Party: Cancer Research Campaign (King's Cambridge) trial for early breast cancer. Lancet 2: 55-60, 1980
4. Senofsky GM, Moffat FL Jr, Davis K, et al.: Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 126: 1336-1342, 1991
5. Donegan WL: Surgical clinical trials. Cancer 53: 691-699, 1984
6. Fentiman IS, Mansel RE: The axilla: Not a no-go zone. Lancet 337: 221-223, 1991
7. Noguchi M, Miwa K, Michigishi T, et al.: The role of axillary lymph node dissection in breast cancer management. Breast Cancer 4: 143-153, 1997
8. Kissin MW, Querci della Rovere G, Easton D, et al.: Risk of lymphedema following the treatment of breast cancer. Br J Surg 73: 580-584, 1986
9. Wazer DE, Erhan JK, Robert NJ, et al.: Breast conservation in early women for clinically negative axillary lymph nodes without axillary dissection. Cancer 74: 878-883, 1994
10. Feigelson BJ, Acosta JA, Feigelson HS, et al.: T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissecton. Am J Surg 172: 487-490, 1996
11. Silverstein MJ, Gierson ED, Waisman JR, et al.: Axillary lymph node dissection for T1a breast carcinoma: Is it indicated? Cancer 73: 664-667, 1994
12. Cady B: The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 73: 505-508, 1994
13. Chadha M, Chabon AB, Friedmann P, et al.: Predictors of axillary lymph node metastases in patients with T1 breast cancer. Cancer 73: 350-353, 1994
14. Greco M, Agresti R, Raselli R, et al.: Axillary dissection can be avoided in selected breast cancer patients: Analysis of 401 cases. Anticancer Res 16: 3913-3918, 1996
15. Noguchi M, Katev N, Miyazaki I: Diagnosis of axillary lymph node metastases in patients with breast cancer. Breast Cancer Res Treat 40: 283-293, 1996
16. Giuliano AE, Kirgan DM, Guenther JM, Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220: 391-401, 1994
17. Krag DN, Weaver DL, Alex C, Fairbank JT: Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2: 335-340, 1993
18. Albertini JA, Lyman GH, Cox C, et al.: Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276: 1818-1822, 1996
19. Pijpers R, Meijer S, Hockstra OS, et al.: Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 38: 366-368, 1997
20. Veronesi U, Pagnelli G, Galimberti V, et al.: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnode. Lancet 349: 1864-1867, 1997
21. Noguchi M, Kawahara F, Tsugawa K, et al.: Sentinel lymphadenectomy in breast cancer: Alternative to routine axillary dissection. Breast Cancer 5: 1-7, 1998
22. Cox CE, Pendas S, Joseph E, et al.: Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 5: 645-653, 1998
23. Giuliano AE, Dale PS, Turner RR, et al.: Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222: 394-401, 1995
24. International Union Against Cancer (UICC): Breast tumors (ICD-0 C-50). In: Sobin LH, Wittekind Ch (eds) TNM Classification of Malignant Tumours. 5th Edition. Wiley, New York, 1997. pp 123-130
25. Noguchi M, Tsugawa K, Kawahara F, et al.: Dye-guided sentinel lymphadenectomy in clinically node-negative or nodepositive breast cancer patients. Breast Cancer 5: 381-387, 1998
26. O'Hea BJ, Hill ADK, El-Shirbiny AM, et al.: Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 186: 423-427, 1998
27. Japan Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. 12th Edition. Kanehara, Tokyo, 1996: pp 19-34
28. The World Health Organization: The World Health Organization histological typing of breast tumors. Am J Clin Pathol 78: 806-816, 1982
29. Giuliano AE: Sentinel lymphadenectomy in primary breast carcinoma: An alternative to routine axillary dissection. J Surg Oncol 62(2): 75-77, 1996
30. Borgstein PJ, Pijpers R, Comans EF, et al.: Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186: 275-283, 1998
31. Gulec SA, Moffat FL, Carrol RG, Krag DN: Gamma probe guided sentinel node biopsy in breast cancer. GJ Nucl Med 41: 251-261, 1997
32. Kramer EL: Lymphoscintigraphy: Radiopharmaceutical selection and methods. Nucl Med Biol 17: 57-63, 1990
33. Turner RR, Ollila DW, Krasne DL, Giuliano AG: Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 226: 271-278, 1997
34. Offodile R, Hoh C, Barsky SH, et al.: Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabelled dextran. Cancer 82: 1704-1708, 1998
35. Giuliano AE: Sentinel lymphadenectomy: A new axillary staging procedure for primary breast carcinoma. Breast Dis 7: 16-17, 1996
36. Hadjiminas DJ, Burke M: Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance. Br J Surg 81: 1615-1616, 1994
37. Fisher CJ, Boyle S, Burke M, Price AB: Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance. Br J Surg 80: 457-458, 1993
38. McGuire WL: Adjuvant therapy of node-negative breast cancer. N Engl J Med 320: 525-527, 1989
39. Mansour EG, Gray R, Shatila AH, et al.: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320: 485-490, 1989
40. Fisher ER, Swamidoss S, Lee CH, et al.: Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42: 2025-2031, 1978
41. Kingsley WB, Peters GN, Check JH: What constitutes adequate study of axillary lymph nodes in breast cancer? Ann Surg 201: 311-314, 1985
42. Ilainsworth PJ, Tjandra JJ, Stillwell RG, et al.: Detection and significance of occult metastasis in node-negative breast cancer. Br J Surg 80: 459-463, 1993
43. Noguchi M, Tsugawa K, Taniya T, Miwa K: The role of internal mammary lymph node metastases in the management of breast cancer. Breast Cancer 5: 117-125, 1998
44. Krag D, Weaver D, Ashikaga T, et al.: The sentinel node in breast cancer. A multicenter validation study. New Engl J Med 339: 941-946, 1998
45. Noguchi M: Comment on "Improved axillary staging of breast cancer with sentinel lymphadenectomy". Ann Surg 225: 126-127, 1997
46. Veronesi U, Cascinelli N, Greco M, et al.: Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 202: 702-707, 1985
47. Cody HS, Urban JA: Internal mammary node status: A major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 2: 32-37, 1995
48. Cote RJ, Rosen PP, Old LJ, Osborne MP: Detection of bone marrow micrometastases in patients with early-stage breast cancer. Diag Oncol 1: 37-42, 1991
49. Dearnaley DP, Ormerod MG, Sloane JP: Micrometastases in breast cancer: Long-term follow-up of the first patient cohort. Eur J Cancer 27(12): 236-239, 1991
50. Mansi JL, Easton D, Berger U, et al.: Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up. Eur J Cancer 27(12): 1552-1555, 1991
51. Diel IJ, Kaufmann M, Goerner R, et al.: Detection of tumor cells in bone marrow of patients primary breat cancer: A prognostic factor for distant metastasis. J Clin Oncol 10(10): 1534-1539, 1992
52. Harbeck N, Untch M, Pache L, Eiermann W: Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 69: 566-571, 1994
53. Molino A, Pelosi G, Turazza M, et al.: Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat 42: 23-30, 1997